万邦德(002082.SZ)：在渐冻症领域布局了新药研发项目

Core Insights - Wanbangde (002082.SZ) is advancing new drug development projects in the field of amyotrophic lateral sclerosis (ALS) and has secured core patent authorization for a differentiated MCR cyclic peptide in the metabolic field [1] Group 1 - The company has laid out new drug research projects specifically targeting ALS [1] - Wanbangde has achieved core patent authorization for its differentiated MCR cyclic peptide [1] - Both the ALS and metabolic projects are progressing steadily [1]